Cyclacel Pharma (CYCC) Income Statement

Click line-items for a historical chart and %

Collaboration and research and development revenue
Product revenue
Grant revenue	205K
Total revenue	205K
Cost of goods sold
Research and development	2.41M
Selling, general and administrative	1.27M
Goodwill and intangibles impairment
Restructuring costs
Total operating expenses
Operating loss	-3.48M
Costs associated with aborted 2004 IPO
Payment under guarantee
Change in valuation of derivative
Change in valuation of warrants
Warrant re-pricing
Foreign exchange (losses)/gains	51K
Interest income	8K
Interest expense
Total other income (expense)	77K
Loss before taxes
Income tax benefit	454K
Net loss	-2.95M
Dividends on preferred ordinary shares
Deemed dividend on convertible exchangeable preferred shares
Dividend on convertible exchangeable preferred shares
Net loss applicable to common shareholders	-3M
Net loss per share- Basic and diluted
Weighted average common shares outstanding

Entities mentioned with CYCC

View All Entities